FOLFOX-HAIC plus Donafenib and Pucotenlimab for Advanced Liver Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three treatments: a special way to deliver chemotherapy directly to the liver (FOLFOX-HAIC), plus two oral and injectable immunotherapy drugs (Donafenib and Pucotenlimab). It is for people with advanced liver cancer (HCC) who have not had prior systemic therapy and whose tumors cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75
- Diagnosed with hepatocellular carcinoma that cannot be removed by surgery (unresectable) or has spread
- No prior cancer treatment that goes throughout the body (systemic therapy) for advanced disease
- Good physical condition (able to take care of yourself and up and about more than half of the day)
- Adequate organ function (bone marrow, liver, kidneys) as per standard lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study looks at combining donafenib (a targeted therapy) with an immunotherapy drug (PD-1/L1 inhibitor) and either TACE or HAIC (two types of minimally invasive treatments for liver tumors) as a first treatment for people with liver cancer that cannot be removed by surgery. It aims to see how well this combination works and how safe it is.
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.